Finerenone 1050477-31-0
17 Inquiries
1050477-31-0
shanghai
as required
2023-01-01
13-Dimethyladamantane,1-Bromo-35-dimethyladamantane,perhydroacenaphthylene,4-[1,1-bis(4-hydroxyphenyl)ethyl]phenol,CYCLOBUTANE-1,2-DICARBOXYLIC ACID DIMETHYL ESTER, TRANS
-
Product Description
-
Seller Information
-
Inquiry History
-
DescriptionECHEMI Editorial ReferenceFinerenone is a novel mineralocorticoid receptor antagonist that has the effect of delaying the progression of chronic kidney disease. Some people may be aware of two other mineralocorticoid receptor antagonists: the diuretic antihypertensive drug spironolactone, and eplerenone.Finerenone is their cognate derivative and is a third-generation mineralocorticoid receptor antagonist. So far, finerenone is the only nonsteroidal mineralocorticoid receptor antagonist to be FDA approved. Finerenone was granted FDA approval on 9 July 2021, followed by the EMA approval on 11 March 2022.Basic Info
-
Product Name:
Finerenone
Other Name:Finerenone (BAY 94-8862);(4S)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridine-3-carboxamide;BAY 94-8862;BAY948862;1,6-Naphthyridine-3-carboxamide, 4-(4-cyano-2-methoxyphenyl)-5-ethoxy-1,4-dihydro-2,8-dimethyl-, (4S)-;Finerone;Mr Neri ketone;(S)-4-(4-Cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridine-3-carboxamide
CAS No.:1050477-31-0
Molecular Formula:C21H22N4O3
InChIKeys:BTBHLEZXCOBLCY-QGZVFWFLSA-N
Molecular Weight:378.42
Exact Mass:378.42
Color/Form:White to off-white
Categories:
Characteristics-
λmax:
255 nm
Density:1.29±0.1 g/cm3(Predicted)
Boiling Point:554.7±50.0 °C(Predicted)
PKA:14.76±0.40(Predicted)
Critical Temperature & Pressure:-20°C
-
-
Seller Information
-
Business Type:
Trader
-
Main Products:
13-Dimethyladamantane,1-Bromo-35-dimethyladamantane,perhydroacenaphthylene,4-[1,1-bis(4-hydroxyphenyl)ethyl]phenol,CYCLOBUTANE-1,2-DICARBOXYLIC ACID DIMETHYL ESTER, TRANS
-
Location:
Room 1623,Building A, ZhongqiaoCenter,Goverment District,Hefei city,Anhui Province,China
-
Payment Terms:
TT against copy of documents,D/P,L/C,D/A,TT against B/L draft before shipment,100% TT in advance
-
Average lead Time:
7
-
Total Annual Revenue:
$1 million-$2.5 million
-
Total Employees:
5-10
-
Year of Establishment:
2019
-
-
Inquiry History17 Inquiries
Country Product Purchase Quantity Date Posted 
India
Finerenone 95%
10.00 KG Sep 10, 2025 
Pakistan
Finerenone
2 KG Mar 18, 2026
Pakistan
Finerenone
10 G Jan 14, 2026
Pakistan
Finerenone
1 KG Dec 4, 2025 
Bangladesh
Finerenone
50 KG Dec 1, 2025
Pakistan
Finerenone
1 KG Jun 28, 2024
Pakistan
FINERENONE
200 G Jun 3, 2026
Pakistan
Finerenone
13 KG Jul 22, 2024
India
Finerenone
50 KG Jan 3, 2024
India
Finerenone
1.00 KG Dec 19, 2023
India
Finerenone
1.00 KG Dec 11, 2023 
Indonesia
Finerenone api
1 KG Oct 7, 2023 
Palestine
Finerenone 1050477-31-0
1 KG Mar 17, 2025
India
URSODEOXYCHOLIC ACID
10.00 KG Mar 6, 2024
India
Acarbose
10.00 KG Mar 6, 2024
India
Upadacitinib
10.00 KG Mar 6, 2024
India
Ripretinib
10.00 KG Mar 6, 2024 Post an enquiry for this product